Hi
@workingdog,
These numbers might interest you in light of your statement. This is a Quarterly wrapup of the sector for the Q4 period. I have also included the Aussie 5-year and Global 10-year Cannabis index as a summary which goes to your remarks, as well.
The only comment I have is that these Revenues are disgraceful after five years of business and are less than the double previous quarter's revenue that I would have been looking/hoping for after a rebranding with a soft launch. However, still, it indicates that the company has started again, as I believe they mentioned. There is still a lot of tidying up, but it is worth taking a close look a the distress the whole sector is in and why I previously mentioned a 10-year prove-up. The Aussie Index does show a slight turn up in the share price curve for July 1, now we are at 5 years.
Trying to find some glimmer of hope here, and looking at the negative cash flow, comparing them to the rest of the sector; if they can improve and double receipts again by the next quarter and keep operating costs low and maintain a healthy fwd funding, then they may be on target for signs of sustained profits profit by six quarters, i.e. Q1 -23/24. I will continue to be on the hammer and chase them over medications and also for the AGM later in the year where I will have my say in voting.
It was great to see Andrew Kavasilas still working with them.
View attachment 4560598
AUSSIE CANNABIS INDEX
View attachment 4560613
GLOBAL CANNABIS INDEX 10 YEARS
View attachment 4560622
